

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
25 April 2002 (25.04.2002)

PCT

(10) International Publication Number
WO 02/032900 A3

(51) International Patent Classification⁷: C07D 471/04, A61K 31/4178, 31/437, A61P 29/00, C07D 235/08, 491/04, 473/00, 521/00, 401/06, 401/04, 417/12, 403/12, 401/12, 235/30, 417/04, 403/04, 403/06 // (C07D 471/04, 235:00, 221:00) (C07D 491/04, 317:00, 235:00) (C07D 491/04, 319:00, 235:00)

(21) International Application Number: PCT/IB01/01940

(22) International Filing Date: 15 October 2001 (15.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/241,825 19 October 2000 (19.10.2000) US

(71) Applicant (for JP only): PFIZER PHARMACEUTICALS INC. [JP/JP]; Mitsui Building, 1-1, Nishi-shinjuku 2-chome, Shinjuku-ku, Tokyo 163-0461 (JP).

(71) Applicant (for all designated States except JP, US): PFIZER INC. [US/US]; 201 Tabor Road, Morris Plain, NJ 07950 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): NAKAO, Kazunari [JP/JP]; Pfizer Global Research & Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). OKUMURA, Yoshiyuki [JP/JP]; Pfizer Global Research & Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). MATSUMIZU, Miyako [JP/JP]; Pfizer Global Research & Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). UNEO, Naomi [JP/JP]; Pfizer Global

Research & Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). HASHIZUME, Yoshinobu [JP/JP]; Pfizer Global Research & Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). KATO, Tomoki [JP/JP]; Pfizer Global Research & Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). KAWAI, Akiyoshi [JP/JP]; Pfizer Global Research & Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). MIYAKE, Yoriko [JP/JP]; Pfizer Global Research & Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). NUKUI, Seiji [JP/JP]; Pfizer Global Research & Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). SHINJO, Katsuhiko [JP/JP]; Pfizer Global Research & Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). TANIGUCHI, Kana [JP/JP]; Pfizer Global Research & Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP).


(74) Agents: LUMB, Trevor, J. et al.; 201 Tabor Road, Morris Plains, NJ 07950 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

[Continued on next page]

(54) Title: ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS



(I)

(57) Abstract: This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y¹, Y², Y³, and Y⁴ are independently selected from N, CH, etc.; R¹ is H, C₁₋₈ alkyl, etc.; Q¹ is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is C₁₋₆ alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R² is H, C₁₋₄ alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, C₁₋₄ alkyl, etc.; m is 0, 1 or 2; R³ and R⁴ are independently selected from H and C₁₋₄ alkyl; R⁵ is H, C₁₋₄ alkyl, etc.; Q² is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from

O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglandin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.



IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:
8 August 2002

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.